1 |
NCT00500487 |
Completed |
Therapeutic Schools: Affect Management and HIV Prevention |
|
- Behavioral: Affect Management
- Behavioral: HIV Prevention Skills
- Behavioral: General Health Promotion
|
Interventional |
Phase 1 |
- Rhode Island Hospital
- University of Chicago
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Adolescent-reported condom use
|
420 |
All |
13 Years to 18 Years (Child, Adult) |
NCT00500487 |
R01MH066641 |
|
April 2003 |
June 2010 |
June 2010 |
July 12, 2007 |
January 12, 2015 |
|
- Rhode Island Hospital
Providence, Rhode Island, United States
|
2 |
NCT00502944 |
Completed Has Results |
Two Approaches to Routine HIV Testing in a Hospital Emergency Department |
|
- Behavioral: Counselor-based HIV screening
- Behavioral: Emergency staff member-based HIV screening
|
Interventional |
Not Applicable |
- Massachusetts General Hospital
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Screening
|
- Linkage to Care of Newly Diagnosed HIV Infected Participants
- Overall Rapid HIV Testing Rate
|
4855 |
All |
18 Years and older (Adult, Senior) |
NCT00502944 |
R01MH073445 DAHBR 9A-ASPQ |
|
February 2007 |
July 2008 |
July 2008 |
July 18, 2007 |
July 19, 2012 |
July 13, 2012 |
- Brigham and Women's Hospital
Boston, Massachusetts, United States
|
3 |
NCT00505401 |
Completed |
Phase I Safety and Immunogenicity Vaccine Trial Against HIV/AIDS |
|
- Biological: recombinant HIV-1 Tat protein
|
Interventional |
Phase 1 |
- Istituto Superiore di Sanità
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- Assessment of product safety included clinical monitoring of volunteers for local and systemic adverse reactions during the course of the trial and monitoring of haematological, biochemical, virological and immunological parameters
- To qualify Tat protein as immunogenic, volunteers were monitored for anti-Tat specific antibodies (IgM, IgG, IgA), anti-Tat proliferative response and in vitro γIFN and IL-4 production by PBMC before vaccination and in response to Tat vaccine.
|
27 |
All |
18 Years to 50 Years (Adult) |
NCT00505401 |
ISST-001 |
ISST-001 |
December 2003 |
|
November 2007 |
July 23, 2007 |
March 1, 2011 |
|
- San Raffaele Hospital
Milan, Italy - Hospital Spallanzani
Rome, Italy - San Gallicano Hospital
Rome, Italy - University of Rome "La Sapienza"
Rome, Italy
|
4 |
NCT00511368 |
Completed |
Phase 2 Safety and Efficacy Study of Bevirimat Functional Monotherapy in HIV Treatment-Experienced Patients for 2 Weeks* |
|
- Drug: matching placebo
- Drug: Bevirimat
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- HIV-1 RNA change from baseline over the first 14 days of study
- safety and tolerability; pharmacokinetics
|
92 |
All |
18 Years to 65 Years (Adult) |
NCT00511368 |
PA103001-04 Study 203 |
|
April 2006 |
July 2008 |
July 2008 |
August 3, 2007 |
January 20, 2010 |
|
- UCLA Medical Center
Los Angeles, California, United States - Quest Clinical Research
San Francisco, California, United States - University of Colorado Health Science Center
Denver, Colorado, United States - (and 15 more...)
|
5 |
NCT00503308 |
Completed Has Results |
HIV Testing Strategies in the Perinatal Setting |
- HIV Infections
- Pregnancy Related
|
- Procedure: Abbreviated HIV test counseling
|
Interventional |
Not Applicable |
- University of California, San Francisco
- Pfizer
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Health Services Research
|
- Satisfaction With HIV Testing Experience (O'Connor Decisional Conflict Scale)
|
281 |
Female |
16 Years and older (Child, Adult, Senior) |
NCT00503308 |
2004-0319 |
|
October 2006 |
September 2007 |
February 2008 |
July 18, 2007 |
May 22, 2015 |
July 1, 2011 |
- UCSF, San Francisco General Hospital
San Francisco, California, United States
|
6 |
NCT00498056 |
Withdrawn |
Safety and Effectiveness of an HIV DNA Vaccine Followed by an HIV Adenoviral Vector Vaccine for Prevention of HIV Infection in the Americas and Africa |
|
- Biological: VRC-HIVDNA016-00-VP
- Biological: VRC-HIVADV014-00-VP
- Biological: VRC-HIVDNA016-00-VP placebo
- Biological: VRC-HIVADV014-00-VP placebo
|
Interventional |
Phase 2 |
- National Institute of Allergy and Infectious Diseases (NIAID)
- Centers for Disease Control and Prevention
- HIV Vaccine Trials Network
- (and 3 more...)
|
NIH / U.S. Fed / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Prevention
|
- Acquisition of HIV infection, reduction in viral load in those who become infected, and adverse events (AEs)
- Seroconversion with HIV RNA or HIV DNA detection, average of two viral load measurements, and AEs graded on the DAIDS AE Grading Table
|
0 |
All |
18 Years to 45 Years (Adult) |
NCT00498056 |
PAVE 100 10500 |
|
|
|
|
July 9, 2007 |
March 27, 2012 |
|
|
7 |
NCT00508222 |
Completed |
Kaletra Monotherapy in HIV/HCV Co-infected Subjects |
|
|
Interventional |
Phase 3 |
- Ottawa Hospital Research Institute
- Abbott
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The primary objective of this study is to assess the safety and efficacy of Kaletra® (lopinavir/ritonavir) monotherapy in the treatment of patients co-infected with HIV and HCV.
- To investigate and compare the pharmacokinetics (PK) of Kaletra® monotherapy at steady-state between co-infected subjects with advanced liver fibrosis (stage 3-4) and those with minimal liver disease (stage 0-2)
- To study compliance of subjects
|
22 |
All |
18 Years and older (Adult, Senior) |
NCT00508222 |
2007217-01H A06-321 |
|
June 2007 |
March 2011 |
April 2011 |
July 27, 2007 |
May 30, 2012 |
|
- University of British Columbia
Vancouver, British Columbia, Canada - The Ottawa Hospital, General Campus
Ottawa, Ontario, Canada
|
8 |
NCT00504452 |
Terminated |
Safety and Efficacy Study of KP-1461 to Treat ART-Experienced HIV+ Patients |
|
|
Interventional |
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To evaluate the safety and tolerability of KP-1461 for 124 days in treatment-experienced, HIV-1-infected subjects.
- To evaluate the antiviral activity (eg., CD4 count, HIV RNA count) of KP-1461 for 124 days in treatment-experienced, HIV-1-infected subjects.
|
27 |
All |
18 Years to 65 Years (Adult) |
NCT00504452 |
KP-1461-201 |
|
July 2007 |
September 2008 |
June 2009 |
July 20, 2007 |
November 7, 2011 |
|
- Health for Life Clinic
Little Rock, Arkansas, United States - Living Hope Clinical Foundation
Long Beach, California, United States - Light Source Medical/U. of Southern California
Los Angeles, California, United States - (and 28 more...)
|
9 |
NCT00510497 |
Completed Has Results |
Autologous Dendritic Cell Vaccine in HIV1 Infection |
|
- Biological: Autologous HIV-1 ApB DC Vaccine
|
Interventional |
Phase 1 Phase 2 |
- Sharon Riddler
- National Institute of Allergy and Infectious Diseases (NIAID)
- University of Pittsburgh
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety and Tolerability of Autologous HIV-1 ApB DC Vaccine.
- Virologic Efficacy (HIV-1 Viral Load at End of ATI Minus Viral Load Prior to ART)
|
11 |
All |
18 Years and older (Adult, Senior) |
NCT00510497 |
Riddler 055794 5U19AI055794 |
|
July 2007 |
September 2012 |
September 2012 |
August 2, 2007 |
June 16, 2016 |
April 4, 2016 |
- University of Pittsburgh
Pittsburgh, Pennsylvania, United States
|
10 |
NCT00510237 |
Completed |
Intervention for Newly Diagnosed Youth With HIV |
|
- Behavioral: "Adolescents Coping, Connecting, Empowering, and Protecting Together" (Project ACCEPT)
|
Interventional |
Not Applicable |
- University of North Carolina, Chapel Hill
- National Institute on Drug Abuse (NIDA)
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- The best procedures for a larger trial (e.g. timing, content etc. of ACASI administration)
- The appropriateness of specific instruments proposed.
- The perceived sensitivity of measures to change over time.
|
50 |
All |
16 Years to 24 Years (Child, Adult) |
NCT00510237 |
ATN 068 |
|
February 2007 |
June 2008 |
January 2009 |
August 1, 2007 |
March 6, 2017 |
|
- University of Miami School of Medicine
Miami, Florida, United States - John Stroger Jr. Hospital of Cook County
Chicago, Illinois, United States - Montefiore Medical Center
Bronx, New York, United States - St. Jude Children's Research Hospital
Memphis, Tennessee, United States
|
11 |
NCT00497081 |
Completed Has Results |
Mirtazapine to Reduce Methamphetamine Use Among MSM With High-risk HIV Behaviors |
- Substance Abuse
- HIV Infections
|
- Drug: mirtazapine
- Drug: placebo
|
Interventional |
Phase 2 |
- San Francisco Department of Public Health
- National Institute on Drug Abuse (NIDA)
- Public Health Foundation Enterprises, Inc.
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Number of Positive Methamphetamine Urine Tests, Comparing Baseline (Week 0) to Final Visit (Week 12).
- Proportion of Days With Recorded Pill Bottle Opening, as Determined by MEMS.
- Frequency of Adverse Events Reported
|
60 |
Male |
18 Years to 60 Years (Adult) |
NCT00497081 |
1R01DA022155-01 R01DA022155 DPMC |
|
May 2007 |
March 2010 |
March 2010 |
July 6, 2007 |
January 5, 2015 |
October 20, 2014 |
- San Francisco Department of Public Health, Substance Use Research Unit
San Francisco, California, United States
|
12 |
NCT00497055 |
Completed Has Results |
Aripiprazole Treatment for Methamphetamine Dependence Among High-risk Individuals |
- Substance Abuse
- HIV Infections
|
- Drug: Aripiprazole
- Drug: Placebo
|
Interventional |
Phase 2 |
- San Francisco Department of Public Health
- National Institute on Drug Abuse (NIDA)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- To Test the Hypothesis That Aripiprazole 20 mg Daily Will Reduce Methamphetamine Use Significantly More Than Placebo Among Methamphetamine-dependent Individuals.
- To Measure the Acceptability of Aripiprazole and Placebo Among Methamphetamine-dependent Individuals, by Determining (Via Electronic Pill Caps [MEMS or Medication Event Monitoring System]) Medication Adherence to Aripiprazole and Placebo.
- To Measure the Safety and Tolerability of Aripiprazole and Placebo Among Methamphetamine-dependent Individuals, as Determined by the Number of Adverse Clinical Events in the Aripiprazole and Placebo Arms.
|
90 |
All |
18 Years to 60 Years (Adult) |
NCT00497055 |
1R01DA022190-01 1R01DA023387-01 DPMC |
|
March 2009 |
March 2012 |
March 2012 |
July 6, 2007 |
March 24, 2014 |
March 24, 2014 |
- San Francisco Department of Public Health, AIDS Office
San Francisco, California, United States
|
13 |
NCT00503633 |
Completed |
Biomarkers of Insomnia and Fatigue in HIV/AIDS (Symptoms and Genetics Study) |
|
|
Observational |
|
- University of California, San Francisco
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
|
350 |
All |
18 Years and older (Adult, Senior) |
NCT00503633 |
SAG |
SAG |
March 2005 |
May 2009 |
May 2009 |
July 19, 2007 |
June 23, 2010 |
|
- University of California, San Francisco
San Francisco, California, United States
|
14 |
NCT00503230 |
Completed |
Reducing Ethnic Health Disparities: Motivating HIV+ Latinos to Quit Smoking |
- Tobacco Dependence
- HIV Infections
|
- Behavioral: Standard Care Intervention (SCI)
- Behavioral: Culturally Tailored Intervention (CTI)
|
Interventional |
Phase 3 |
- Butler Hospital
- National Institute on Drug Abuse (NIDA)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
400 |
All |
18 Years and older (Adult, Senior) |
NCT00503230 |
R01DA018079 |
AURORA |
October 2005 |
July 2011 |
July 2011 |
July 18, 2007 |
May 3, 2013 |
|
- Lowell Community Health Center
Lowell, Massachusetts, United States - Greater New Bedford Community Center
New Bedford, Massachusetts, United States - Dimock Community Health Center
Roxbury, Massachusetts, United States - (and 5 more...)
|
15 |
NCT00511056 |
Completed |
Adherence and Risk Behaviour in Patients With HIV Infection Receiving Antiretroviral Therapy |
|
|
Observational |
|
- The HIV Netherlands Australia Thailand Research Collaboration
- Kirby Institute
|
Other |
- Observational Model: Cohort
- Time Perspective: Cross-Sectional
|
- The relationship between sexual risk behavior and adherence to HIV medications and how do these behaviors relate to patient beliefs about HIV transmission.
|
700 |
All |
18 Years and older (Adult, Senior) |
NCT00511056 |
HIV-NAT Amendment II to 006 |
ARB |
September 2007 |
January 2009 |
December 2009 |
August 3, 2007 |
July 11, 2011 |
|
- HIV-NAT, Thai Red Cross AIDS Research Centre
Bangkok, Thailand
|
16 |
NCT00499876 |
Completed |
The Effect of Malaria on Disease Progression of HIV/AIDS |
|
- Drug: mefloquine
- Other: placebo
|
Interventional |
Not Applicable |
- London School of Hygiene and Tropical Medicine
- Noguchi Memorial Institute for Medical Research
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Supportive Care
|
- Measure the effects of antimalarials on CD4 cell count decline and HIV viral load increase in study patients
- Measure the effect of malaria prophylaxis on malaria parasitaemia and haemoglobin levels in study patients
|
197 |
All |
19 Years and older (Adult, Senior) |
NCT00499876 |
REG_9 KATH_GMP_1 |
|
October 2007 |
October 2008 |
December 2009 |
July 12, 2007 |
January 26, 2017 |
|
- Komfo Anokye Teaching Hospital
Kumasi, Ghana
|
17 |
NCT00502827 |
Completed |
Smoking Cessation for HIV/AIDS Patients |
- Human Immunodeficiency Virus
|
- Behavioral: Cell Phone Intervention
- Other: Recommended Standard of Care
|
Interventional |
Not Applicable |
- M.D. Anderson Cancer Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Proportion of participants in the two intervention groups who are abstinent as measured by point prevalence
|
706 |
All |
18 Years and older (Adult, Senior) |
NCT00502827 |
2003-0784 NCI-2012-02109 |
|
January 2004 |
April 2015 |
April 2015 |
July 18, 2007 |
February 26, 2016 |
|
- Thomas Street Clinic
Houston, Texas, United States - University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
18 |
NCT00509340 |
Terminated |
Cognitive Behavioral Therapy to Help HIV Infected Adults With Depression to Adhere to Antiretroviral Therapy |
|
- Behavioral: Cognitive behavioral therapy (CBT)
|
Interventional |
Phase 1 |
- RAND
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Microelectronic medication adherence
- Self-reported depression
|
7 |
All |
18 Years to 60 Years (Adult) |
NCT00509340 |
R34MH077503 DAHBR 9A-ASNM |
|
June 2007 |
June 2013 |
June 2013 |
July 31, 2007 |
June 21, 2013 |
|
- LA Biomedical Institute at Harbor-UCLA
Torrance, California, United States
|
19 |
NCT00507221 |
Completed |
Empiric Therapy of Helminth Co-infection to Reduce HIV-1 Disease Progression |
- HIV Infections
- Helminthiasis
|
- Drug: Albendazole
- Drug: Praziquantel
- Drug: Current standard of care in Kenya
|
Interventional |
Not Applicable |
- University of Washington
- Centers for Disease Control and Prevention
- Kenya Medical Research Institute
|
Other / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- CD4 count
- HIV-1 RNA level
- Markers of clinical disease progression as measured by WHO staging criteria
|
948 |
All |
18 Years and older (Adult, Senior) |
NCT00507221 |
32274-B KEMRI SSC #1251; 07-6824-B 01 |
THE or PHE |
February 2008 |
July 2011 |
October 2011 |
July 26, 2007 |
November 20, 2014 |
|
- Kenya Medical Research Institute
Nairobi, Kenya
|
20 |
NCT00503347 |
Completed |
Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus |
- Hepatitis C Virus
- Hiv Infections
|
|
Interventional |
Phase 1 |
- Peregrine Pharmaceuticals
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- • Adverse events • Laboratory evaluations • Human anti-chimeric antibody • Pharmacokinetic analysis
- Blood levels of HCV RNA and HIV RNA (PCR)
|
24 |
All |
18 Years and older (Adult, Senior) |
NCT00503347 |
PPHM 0603 |
|
July 2007 |
March 2011 |
June 2011 |
July 18, 2007 |
June 9, 2011 |
|
- Impact Clinical Research
Los Angeles, California, United States - Orange Coast Medical Center
Newport Beach, California, United States - AIDS Research Consortium of Atlanta
Atlanta, Georgia, United States - (and 3 more...)
|
21 |
NCT00499434 |
Unknown † |
Correlation Between Cytokines and Hepatic Histology in Patients Infected by HIV-1 and the Hepatitis-C Virus |
- Acquired Immune Deficiency Syndrome
- Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted
- HIV Infections
|
|
Observational |
|
- UPECLIN HC FM Botucatu Unesp
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- This study aims at correlating TNF-α, INF-γ, IL-2, IL-4, IL-10 and TGF-β values as dosed by ELISA and mRNA expression by real-time PCR with histopathological hepatic biopsy findings in individuals with HIV/HCV coinfection
- This study aims at correlating TNF-α, INF-γ, IL-2, IL-4, IL-10 and TGF-β values as dosed by ELISA and mRNA expression by real-time PCR with CD4 and HIV viremia values in individuals with HIV/HCV coinfection
|
110 |
All |
18 Years to 60 Years (Adult) |
NCT00499434 |
upeclin/HC/FMB-Unesp-14 |
|
August 2007 |
January 2009 |
February 2010 |
July 11, 2007 |
December 4, 2009 |
|
- SAE e Hospital Dia de Aids
Botucatu, Sao Paulo, Brazil
|
22 |
NCT00499187 |
Completed |
Fanconi Syndrome Due to ARVs in HIV-Infected Persons |
- HIV Infections
- Fanconi Syndrome
- Kidney Disease
- Renal Impairment
|
|
Observational |
|
|
Industry |
- Observational Model: Case Control
- Time Perspective: Prospective
|
- Time to TDF discontinuation after diagnosis of Fanconi syndrome
- Time to confirmed resolution of Fanconi syndrome
|
56 |
All |
18 Years and older (Adult, Senior) |
NCT00499187 |
GS-US-104-0353 |
|
September 2007 |
March 2011 |
March 2011 |
July 11, 2007 |
March 17, 2014 |
|
- Los Angeles, California, United States
- Denver, Colorado, United States
- Miami, Florida, United States
- (and 10 more...)
|